Admin – Ology Bio

About Admin

This author has not yet filled in any details.
So far Admin has created 76 blog entries.

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure

Admin2018-08-17T09:49:16+00:00August 17th, 2018|

Ology Bioservices Wins $8.4 Million Defense Department Award to Produce Anti-Ebola Medical Countermeasure ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), announced today that it was awarded an Other Transaction Agreement (OTA) to support the Joint Project Manager Medical Countermeasure Systems (JPM-MCS), a component of the Joint [...]

Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases

Admin2018-08-10T10:19:56+00:00August 7th, 2018|

Barrett PN, Terpening SJ, Snow D, Cobb RR, Kistner O. Vero cell technology for rapid development of inactivated whole virus vaccines for emerging viral diseases. Expert Review of Vaccines. 2017;16(9):883-894. Read More >

Development of a synthetic Vi polysaccharide vaccine for typhoid fever

Admin2018-08-07T11:33:13+00:00August 7th, 2018|

Ni Y, Springer MJ, Guo J, et al. Development of a synthetic Vi polysaccharide vaccine for typhoid fever. Vaccine. 2017;35:7121–7126. Read Here >

An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E

Admin2018-08-10T10:18:32+00:00July 28th, 2018|

Li M, Lee D, Obi CR, Freeberg JK, Farr-Jones S, Tomic MT. An ambient temperature-stable anti toxin of nine co-formulated antibodies for botulism caused by serotypes A, B and E. PLoSONE 2018.13(5):e0197011. Read Here >

Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder.

Admin2018-07-30T10:58:50+00:00July 28th, 2018|

Ball JP, Springer MJ, Ni Y, Finger-Baker I, Martinez J, Hahn J, et al. Intranasal delivery of a bivalent norovirus vaccine formulated in an in situ gelling dry powder. PLoSONE. 2017;12(5):e0177310 Read Here >

Zika Virus: Medical Countermeasure Development Challenges.

Admin2018-08-07T11:52:05+00:00July 28th, 2018|

Malone RW, Homan J, Callahan MV, Glasspool-Malone J, Damodaran L, Schneider ADB, et al. Zika virus: medical countermeasure development challenges. 2016 PLoS Negl Trop Dis. 10(3): e0004530. Read Here >

Preclinical Dose Ranging Studies of a Novel Dry Powder Norovirus Vaccine Formulation

Admin2018-08-07T14:58:48+00:00July 25th, 2018|

Springer MJ, Ni Y, Finger-Baker I, et al. Preclinical dose ranging studies of a novel dry powder norovirus vaccine formulation. Vaccine. 2016;34(12):1452–1458. Read Here>

Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector

Admin2018-07-25T15:30:49+00:00July 24th, 2018|

Ology Bioservices and RAFA Laboratories Announce FDA Approval of the Atropine Autoinjector as a Medical Countermeasure for Chemical Nerve Agents ALACHUA, Fla. & JERUSALEM--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics contract development and manufacturing organization (CDMO), and Rafa Laboratories, Ltd. (Rafa), a leading Israeli pharmaceutical company, today announced that on July 9, 2018, [...]

Ology Bioservices to Develop Vaccine Candidate Against Malaria for The Global Health Initiative Fund

Admin2018-07-14T21:27:07+00:00July 14th, 2018|

Ology Bioservices will develop the large-scale, process development and manufacturing plan and supply the AnAPN1 vaccine candidate for use in ongoing pre-clinical studies and to prepare for subsequent clinical testing.

Ology Bioservices Strengthens Board of Directors

Admin2018-07-14T03:30:20+00:00April 3rd, 2018|

Ology Bioservices Strengthens Board of Directors with Appointment of Industry Veterans James M. Robinson and Gerard Cunningham Former Merck & Co. Executives Bring Deep Expertise in Development and Manufacturing of Vaccines and Biologicals ALACHUA, Fla.--(BUSINESS WIRE)--Ology Bioservices, Inc., a biologics-focused contract development and manufacturing organization (CDMO) serving both government and commercial clients, [...]

12 Next